Favorable Long-Term Outcomes for Operable NSCLC After Neoadjuvant Immunotherapy

(MedPage Today) -- Patients with operable non-small cell lung cancer (NSCLC) had a 5-year overall survival (OS) rate of 80% and a recurrence-free survival (RFS) rate of 60% following neoadjuvant immunotherapy with nivolumab (Opdivo), data from...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news